Provider file · new entrant · verification pending
Trimi: the file as of August 17, 2026
Latest first-party read (September 12, 2026), from the open dataset. Trimi Health (read September 12, 2026 at trytrimi.com): tirzepatide — $125/mo: $125 12-month plan, nothing billed beside it — supply paid at once; flags: prepaid · all sales final; dose policy same price at every dose; labs not advertised; pharmacies 2 named; cancellation: refund in full only if found ineligible at review. semaglutide — $99/mo: $99 12-month plan, nothing billed beside it — supply paid at once; flags: prepaid · all sales final; dose policy same price at every dose; labs not advertised; pharmacies 2 named; cancellation: refund in full only if found ineligible at review. The file below records this site’s earlier, dated read; any figure it carries that the provider’s page no longer prints is kept as dated history and is not ranked. Dated pages, regenerated on every build: compounded tirzepatide online price · compounded semaglutide online price · NexLife true monthly cost · news ledger.
Trimi self-publishes compounded semaglutide from $99/month and tirzepatide from $125/month on annual plans, flat at every dose with no membership fee, naming its 503A pharmacies (VialsRx — Texas board license cited — and GreenwichRx) and claiming licensed providers in all 50 states. Those are serious-looking disclosures — and they are the company’s own claims, from its own materials, including a self-ranking blog that places itself first. Per the tier rules: listed, dated, linked, and not crowned until independently verified. One more disambiguation the market itself keeps flagging: Trimi (trytrimi.com) is not TrimRx — separate, unaffiliated companies.
What the capture shows
Named pharmacies with a citable state license number are a genuine quality signal per the signals file — most sub-$150 stickers can’t produce one. Flat-at-every-dose language, if it survives a checkout walk, would make Trimi a dose-proof peer of the audited anchor at a lower sticker. What’s missing is exactly what the tier system exists to demand: an independent walk confirming all-in totals, dose behavior, exit terms, and BUD-to-shipment alignment.
Open files
Independent price verification · refund and cancellation terms · shipment/BUD alignment · clinical-reachability testing. Any of these closing moves the tier; all of them closing puts the $74-per-expected-point figure on the value podium instead of its watch-list.
Standing rules apply: compounded products are not FDA-approved; trial certificates belong to the brands; tier upgrades require the same audit the anchor passed, and corrections@ outranks this page with dated evidence. Field context: the cost index · tirzepatide value board · semaglutide value board.
Trimi’s published pricing ↗ (plain reference link — not a partner; figures self-published, pending verification)